Serum Institute of India (SII) seeks nod from government to export Covovax to US
According to a communication sent to the government by Prakash Kumar Singh, the Director of Government and Regulatory Affairs at the SII, the shipment is likely to be dispatched on July 3
The Serum Institute of India(SII) has sought for the Union Government’s approval to export 3.2 million doses of Covovax under the brand name Nuvaxovid to the US.
SII manufactures Covovax- the second corona virus vaccine after Covishield by the company, under a license from the vaccine’s developer, US-based Novavax. The export version of the vaccine is called Nuvaxovid, which has also been dispatched by the Pune-based vaccine maker to New Zealand, Netherlands, Australia and Indonesia, where about 100 million doses have been sent.